Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
Boehringer Ingelheim Investigational Site
mi
from
Birmingham, AL
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
Boehringer Ingelheim Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
205.452.01038 Boehringer Ingelheim Investigational Site
mi
from
Encinitas, CA
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
205.452.01038 Boehringer Ingelheim Investigational Site
mi
from
Encinitas, CA
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
1245.25.10103 Boehringer Ingelheim Investigational Site
mi
from
Encino, CA
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
1245.25.10103 Boehringer Ingelheim Investigational Site
mi
from
Encino, CA
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
205.452.01130 Boehringer Ingelheim Investigational Site
mi
from
Atlanta, GA
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
205.452.01130 Boehringer Ingelheim Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
205.452.01330 Boehringer Ingelheim Investigational Site
mi
from
Arlington Heights, IL
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
205.452.01330 Boehringer Ingelheim Investigational Site
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
1199.14.1261 Boehringer Ingelheim Investigational Site
mi
from
Skokie, IL
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
1199.14.1261 Boehringer Ingelheim Investigational Site
mi
from
Skokie, IL
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
1311.4.10100 Boehringer Ingelheim Investigational Site
mi
from
West Dundee, IL
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
1311.4.10100 Boehringer Ingelheim Investigational Site
mi
from
West Dundee, IL
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
1311.4.10044 Boehringer Ingelheim Investigational Site
mi
from
Plainfield, IN
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
1311.4.10044 Boehringer Ingelheim Investigational Site
mi
from
Plainfield, IN
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
1222.29.11002 Boehringer Ingelheim Investigational Site
mi
from
Overland Park, KA
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
1222.29.11002 Boehringer Ingelheim Investigational Site
mi
from
Overland Park, KA
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
1199.14.1172 Boehringer Ingelheim Investigational Site
mi
from
Louisville, KY
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
1199.14.1172 Boehringer Ingelheim Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
205.452.01270 Boehringer Ingelheim Investigational Site
mi
from
Ann Arbor, MI
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
205.452.01270 Boehringer Ingelheim Investigational Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
205.452.01104 Boehringer Ingelheim Investigational Site
mi
from
Fridley, MN
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
205.452.01104 Boehringer Ingelheim Investigational Site
mi
from
Fridley, MN
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
1311.2.10001 Boehringer Ingelheim Investigational Site
mi
from
East Windsor, NJ
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
1311.2.10001 Boehringer Ingelheim Investigational Site
mi
from
East Windsor, NJ
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
Boehringer Ingelheim Investigational Site
mi
from
Charlotte, NC
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
Boehringer Ingelheim Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
Boehringer Ingelheim Investigational Site
mi
from
Cincinnati, OH
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
Boehringer Ingelheim Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
Boehringer Ingelheim Investigational Site
mi
from
Portland, OR
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
Boehringer Ingelheim Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
205.452.01214 Boehringer Ingelheim Investigational Site
mi
from
Johnston, RI
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
205.452.01214 Boehringer Ingelheim Investigational Site
mi
from
Johnston, RI
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
1301.1.5799 Boehringer Ingelheim Investigational Site
mi
from
Webster, TX
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
1301.1.5799 Boehringer Ingelheim Investigational Site
mi
from
Webster, TX
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
1245.25.10004 Boehringer Ingelheim Investigational Site
mi
from
Norfolk, VA
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
1245.25.10004 Boehringer Ingelheim Investigational Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
1199.14.1259 Boehringer Ingelheim Investigational Site
mi
from
Spokane, WA
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
1199.14.1259 Boehringer Ingelheim Investigational Site
mi
from
Spokane, WA
Click here to add this to my saved trials
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated:  12/31/1969
1199.128.10017 Boehringer Ingelheim Investigational Site
mi
from
Saint Louis, MO
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status: Enrolling
Updated: 12/31/1969
1199.128.10017 Boehringer Ingelheim Investigational Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Wallace Medical Group
mi
from
Beverly Hills, CA
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Wallace Medical Group
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Encino Research Center
mi
from
Encino, CA
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Encino Research Center
mi
from
Encino, CA
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
eStudySite
mi
from
La Mesa, CA
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
eStudySite
mi
from
La Mesa, CA
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
eStudySite
mi
from
Oceanside, CA
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
eStudySite
mi
from
Oceanside, CA
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
eStudySite
mi
from
San Diego, CA
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
eStudySite
mi
from
San Diego, CA
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Shahram Jacobs MD, INC
mi
from
Sherman Oaks, CA
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Shahram Jacobs MD, INC
mi
from
Sherman Oaks, CA
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Horizons Clinical Research Center, LLC
mi
from
Denver, CO
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Horizons Clinical Research Center, LLC
mi
from
Denver, CO
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Bioclinical Research Alliance Inc.
mi
from
Miami, FL
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Bioclinical Research Alliance Inc.
mi
from
Miami, FL
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Sanitas Reasearch, LLC
mi
from
Miami, FL
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Sanitas Reasearch, LLC
mi
from
Miami, FL
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Renstar Medical Research
mi
from
Ocala, FL
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Renstar Medical Research
mi
from
Ocala, FL
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Compass Research LLC
mi
from
Orlando, FL
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Compass Research LLC
mi
from
Orlando, FL
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Dawes Fretzin Clinical Research Group, LLC
mi
from
Indianapolis, IN
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Dawes Fretzin Clinical Research Group, LLC
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Radiant Research, Inc.
mi
from
Overland Park, KA
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Radiant Research, Inc.
mi
from
Overland Park, KA
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Bay State Clinical Trials, Inc.
mi
from
Watertown, MA
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Bay State Clinical Trials, Inc.
mi
from
Watertown, MA
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
eStudySite
mi
from
Las Vegas, NV
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
eStudySite
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Radiant Research, Inc.
mi
from
Cincinnati, OH
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Radiant Research, Inc.
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Radiant Research, Inc
mi
from
Columbus, OH
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Radiant Research, Inc
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Radiant Clinical Research
mi
from
Anderson, SC
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Radiant Clinical Research
mi
from
Anderson, SC
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Palmetto Clinical Trial Services Llc
mi
from
Fountain Inn, SC
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Palmetto Clinical Trial Services Llc
mi
from
Fountain Inn, SC
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Radiant Research
mi
from
Greer, SC
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Radiant Research
mi
from
Greer, SC
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Austin Institute for Clinical Research, Inc.
mi
from
Pflugerville, TX
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Austin Institute for Clinical Research, Inc.
mi
from
Pflugerville, TX
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
National Clinical Research - Richmond, Inc.
mi
from
Richmond, VA
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
National Clinical Research - Richmond, Inc.
mi
from
Richmond, VA
Click here to add this to my saved trials
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Medical Centre Asklepii, OOD
mi
from
Dupnitsa,
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Medical Centre Asklepii, OOD
mi
from
Dupnitsa,
Click here to add this to my saved trials
To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adult Patients With Moderate-to-severe Atopic Dermatitis (AD)
A Phase IIa, Double-Blind, Randomised, Placebo-controlled, Exploratory Study to Evaluate the Safety, Biological Activity and Pharmacokinetics of GBR 830 in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Glenmark Investigational Site 1
mi
from
New York, NY
To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adult Patients With Moderate-to-severe Atopic Dermatitis (AD)
A Phase IIa, Double-Blind, Randomised, Placebo-controlled, Exploratory Study to Evaluate the Safety, Biological Activity and Pharmacokinetics of GBR 830 in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Glenmark Investigational Site 1
mi
from
New York, NY
Click here to add this to my saved trials